The Zhitong Finance App learned that Guojin Securities released a research report saying that Xiansheng Pharmaceutical (02096.HK)'s short-term pipeline volume resonates with long-term innovation iterations, and the growth certainty is strong. It predicts that in 2025/2026/2027 it will achieve operating income of 7.63 billion yuan/9.10 billion yuan/11.04 billion yuan, +15.0%/+19.3%/+21.4% year over year, net profit of 1.150 million/1.36 billion yuan, corresponding to EPS of +57.3%/+19.4%/+20.5% 0.64 yuan (112 million shares have been considered for allotment in September 2025). According to DCF's valuation, the corresponding reasonable target price was HK$20.16, which was covered for the first time and gave a “buy” rating.

The Zhitong Finance App learned that Guojin Securities released a research report saying that Xiansheng Pharmaceutical (02096.HK)'s short-term pipeline volume resonates with long-term innovation iterations, and the growth certainty is strong. It predicts that in 2025/2026/2027 it will achieve operating income of 7.63 billion yuan/9.10 billion yuan/11.04 billion yuan, +15.0%/+19.3%/+21.4% year over year, net profit of 1.150 million/1.36 billion yuan, corresponding to EPS of +57.3%/+19.4%/+20.5% 0.64 yuan (112 million shares have been considered for allotment in September 2025). According to DCF's valuation, the corresponding reasonable target price was HK$20.16, which was covered for the first time and gave a “buy” rating.